Abstract:Objectives: To identify the risk factors associated with anti-tuberculosis drug-induced liver injury (AT-DILI) or abnormal living functioning from 757 patients with pulmonary tuberculosis (TB) registered at Nanshan Center for Chronic Disease Control (Nanshan CCDC), Shenzhen, Guangdong Province, China. Design and methods: We identified 757 TB patients who met our inclusion criteria by screening the Hospital Information System (HIS) at Nanshan CCDC. Next, we identified positive cases of AT-DILI or abnormal liver functioning based on results of the first-time liver function tests (LFTs) after taking anti-TB drugs. The χ2 test was used to relate the positive rate with a variety of factors. A logistic regression model was also used to identify statistically significant risk factors. Results: Of the 757 patients, the positive rate of AT-DILI or abnormal liver functioning was 37.9% (287/757). Univariate analysis revealed that the positive rate was 42.91% (212/494) for males and 28.52% (75/263) for females. The positive rate was significantly higher in males ( p <0.001). Patients with an annual income of 9,231–13,845 USD had a significantly higher positive rate (67.35%; 33/49) than those with an income of 1,540–4616 USD (37.97%; 30/79) ( p = 0.022). The most frequent prescription regime among positive cases was a 2 months supply of fixed dose combination Ethambutol Hydrochloride, Pyrazinamide, Rifampicin and Isoniazid Tablets (II) 450 mg) followed by a 4 months supply of fixed dose combination Rifampin and Isoniazid Capsules (2FDC-HRZE half/4FDC-HR) at 56.03% (144/257). The least frequent prescription regime was a 2 months supply of fixed dose combination Rifampin, Isoniazid and Pyrazinamide Capsules with Ethambutol independently followed by a 4 months supply of fixed dose combination Rifampin and Isoniazid Capsules (2FDC-HRZ + EMB/4FDC-HR) at 24.27% (25/103). The difference between these two different regimes was significant ( p = 0.022). With an increase in the duration of medication, patients under various prescription regimes all showed a gradual increase in the positive rate of AT-DILI or abnormal liver functioning. Conclusion: We identified several risk factors for the occurrence of AT-DILI or abnormal liver functioning, including gender, annual income, prescription regime, dosage, and treatment time.

Involvement of Cytochrome P450 1A1 and Glutathione S-Transferase P1 Polymorphisms and Promoter Hypermethylation in the Progression of Anti-Tuberculosis Drug-Induced Liver Injury: A Case–Control Study

Genome-Wide Analysis of DNA Methylation and Antituberculosis Drug-Induced Liver Injury in the Han Chinese Population

CYP2E1, GSTM1 and GSTT1 Genetic Polymorphisms and Susceptibility to Antituberculosis Drug-Induced Hepatotoxicity: a Nested Case-Control Study.

Pharmacogenetic Study Of Drug-Metabolising Enzyme Polymorphisms On The Risk Of Anti-Tuberculosis Drug-Induced Liver Injury: A Meta-Analysis

Drug-metabolising Enzyme Polymorphisms and Predisposition to Anti-Tuberculosis Drug-Induced Liver Injury: a Meta-Analysis.

Study on polymorphisms of genes with susceptibility to drug induced liver injury in a cohort receiving anti-tuberculosis treatment

An Investigation of the Risk Factors Associated With Anti-Tuberculosis Drug-Induced Liver Injury or Abnormal Liver Functioning in 757 Patients With Pulmonary Tuberculosis

The relationship between polymorphisms of N-acetyltransferase 2 genes and anti-tuberculosis drug induced hepatic-injury

Lack of association between genetic polymorphisms of CYP3A4, CYP2C9 and CYP2C19 and antituberculosis drug-induced liver injury in a community-based Chinese population.

Genetic Polymorphisms of SLCO1B1, CYP2E1 and UGT1A1 and Susceptibility to Anti-Tuberculosis Drug-Induced Hepatotoxicity: A Chinese Population-Based Prospective Case–Control Study

Prospective Study Of Aldh1a1 Gene Polymorphisms Associated With Antituberculosis Drug-Induced Liver Injury In Western Chinese Han Population

CYP7A1, BAAT and UGT1A1 Polymorphisms and Susceptibility to Anti-Tuberculosis Drug-Induced Hepatotoxicity.

Genetic Polymorphisms in Antioxidant Enzymes Modulate the Susceptibility of Idiosyncratic Antituberculous Drug-Induced Liver Injury and Treatment Outcomes in Patients with Tuberculosis

Cytochrome P450 2e1 Gene Polymorphisms/Haplotypes And Anti-Tuberculosis Drug-Induced Hepatitis In A Chinese Cohort

Association of DNA methylation, polymorphism and mRNA level of ALAS1 with antituberculosis drug-induced liver injury

TANC1 methylation as a novel biomarker for the diagnosis of patients with anti-tuberculosis drug-induced liver injury

[The Effect of GST M1 and GST T1 Gene Mutations on Anti-Tuberculous Drug Induced Hepatic Injury].

The Association Between HLA-DQB1 Polymorphism and Antituberculosis Drug-Induced Liver Injury: a Case-Control Study.

The genetic variants in calcium signaling related genes influence anti-tuberculosis drug induced liver injury: A prospective study.

Association of POR and PPARα Polymorphisms with Risk of Anti-Tuberculosis Drug-Induced Liver Injury in Western Chinese Han Population

Role of Polymorphic Bile Salt Export Pump (BSEP, ABCB11) Transporters in Anti-Tuberculosis Drug-Induced Liver Injury in a Chinese Cohort